Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses

作为我们现有U54的补充，我们建议将西奈山作为一个协调站点，用于汇总和分析由SeroNet支持的多项肺癌研究的人口统计学、临床和分子数据。这些来自全国知名机构的研究一直在调查肺癌和SARS-CoV-2的交叉点，以探索联合疾病对患者健康的影响，调查导致不良结局的潜在生物学，并了解肺癌疾病和/或治疗对SARS-CoV-2疫苗诱导的免疫反应的影响。为了实现这一目标，我们将利用约瑟夫·芬克尔斯坦领导的西奈山生物信息学小组的丰富专业知识和经验，以及我们在范德比尔特统计局合作伙伴的数据分析能力。

As a supplement to our existing U54, we propose that Mount Sinai serve as a coordinating site for aggregating and analyzing demographic, clinical and molecular data from multiple lung cancer studies supported by SeroNet. These studies, from prominent institutions across the country, have been investigating the intersection of lung cancer and SARS-CoV-2 to explore the impact of the combined diseases on patient health, investigate the underlying biology that leads to poor outcomes and understand the effects of lung cancer disease and/or treatments on SARS-CoV-2 vaccination-induced immune responses. To accomplish this goal, we will leverage the considerable expertise and experience of the Mount Sinai Bio-informatics group, led by Joseph Finkelstein, and the data analysis capabilities of our partners at the Vanderbilt Department of Statistics.